Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
Recruiting · NCT06926179 · Observational (researchers observe without assigning treatment) · Lead sponsor: Peking University Cancer Hospital & Institute
View the official record on ClinicalTrials.gov →Interventions studied
neoadjuvant immunotherapy
What this trial is about
This multicenter retrospective real-world study aims to evaluate the safety, efficacy and survival outcomes of neoadjuvant/induction immunotherapy in patients with non-small cell lung cancer (NSCLC). The study covers diverse treatment pathways, including surgery, definitive radiotherapy, and non-surgical strategies. It addresses gaps in existing trials by establishing a comprehensive cohort spanning neoadjuvant/induction therapy, perioperative management, and follow-up, providing real-world evidence to support treatment decisions in both operable and inoperable cases.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Histologically confirmed non-small cell lung cancer (NSCLC), regardless of the presence of EGFR or ALK sensitive driver gene mutations;
- Clinical staging of IA-IIIC according to the AJCC 8th Edition before neoadjuvant treatment;
- Received at least one cycle of neoadjuvant immunotherapy (with or without chemotherapy);
- Assessed as resectable or potentially resectable by surgical experts prior to treatment.
Exclusion criteria
- Confirmed M1 disease;
- History of previous lung malignancy or other metastatic malignant tumors;
- Participation in other randomized controlled trials involving neoadjuvant treatment;
- Significant missing clinical data.
Where it is running
4 locations listed.
- Peking University Cancer Hospital & Institute - Beijing, Beijing Municipality, China
- Peking University Third Hospital - Beijing, Beijing Municipality, China
- Inner Mongolia Hospital of Peking University Cancer Hospital - Hohhot, Inner Mongolia, China
- The Third Affliated Hospital of Kunming Medical University - Kunming, Yunnan, China